Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
167
-
Total 13F shares, excl. options
-
112M
-
Shares change
-
+8.43M
-
Total reported value, excl. options
-
$390M
-
Value change
-
+$29.5M
-
Put/Call ratio
-
0.7
-
Number of buys
-
69
-
Number of sells
-
-60
-
Price
-
$3.49
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2025
193 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q1 2025.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 112M shares
of 193M outstanding shares and own 57.8% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (23.8M shares), Whitefort Capital Management, LP (13.3M shares), BlackRock, Inc. (12.8M shares), Two Seas Capital LP (9.47M shares), VANGUARD GROUP INC (8.95M shares), STATE STREET CORP (4.36M shares), GEODE CAPITAL MANAGEMENT, LLC (3.54M shares), Woodline Partners LP (2.66M shares), FOURSIXTHREE CAPITAL LP (2.45M shares), and BlackBarn Capital Partners LP (2.34M shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.